Verici Dx Plc (GB:VRCI) has released an update.
Verici Dx Plc is set to present new data at the American Transplant Congress highlighting the role of its TutiviaTM tool in assessing risks of delayed graft function in kidney transplants. The company aims to address an unmet need in identifying rejection risks, showcasing their clinical trial findings to the global transplant community. Verici Dx specializes in developing advanced diagnostics to improve outcomes for transplant patients through AI-assisted transcriptomic analysis.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.
